RPCEC00000322招募中未知

Treatment of lung lesions with autologous stem cells in patients recovered from COVID-19 (COVID-19)

Institute of Hematology and Immunology Dr. Jose Manuel Ballester Santovenia”0 个研究点目标入组 20 人开始时间: 2020年7月3日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

•1. Patient who gives his informed consent.
•2. Negative viral load by PCR.
•3. Over 18 and under 75.
•4. Lung damage evidenced by the criteria of radiological severity in COVID 19 on CT.

•2. Patients with contraindications to the use of IOR® LEUKOCIM.
•3. Patients who have taken amiodarone in the last 3 months, which can cause pulmonary fibrosis.
•4. Patients with malignant tumor in the last 5 years.
•5. Patients with decompensated heart and kidney disease.
•6. Patients with liver disease whose presence of enzyme values 2 times above the upper level of the range of normal values is demonstrated in the blood chemistry.
•7. Patients who have ultrasound images that require further study for diagnosis.
•8. Pregnant women
•9. Patients with severe lung infection who need anti-infective treatment.
•10. Patients with proven viral infections or positive serology.

发起方

Institute of Hematology and Immunology Dr. Jose Manuel Ballester Santovenia”